NCT04164368View on ClinicalTrials.gov

Lenalidomide Combined With R-CHOP(R2-CHOP) in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

October 22, 2019

Primary Completion Date

August 9, 2021

Study Completion Date

August 30, 2023

Conditions
Double Expressor Lymphoma
Interventions
DRUG

Lenalidomide combined with R-CHOP

rituximab 375 mg/m2,ivgtt D1 cyclophosphamide 750 mg/m2 iv D2 vincristine 1.4 mg/m2 \[capped at 2.0 mg\], iv D2 doxorubicin 50 mg/m2 iv D2 prednisone 100 mg/m2 per day PO D2-6 Lenalidomide 25mg PO QD D2-11

Trial Locations (1)

200032

270 Dongan Road, Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER

NCT04164368 - Lenalidomide Combined With R-CHOP(R2-CHOP) in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients | Biotech Hunter | Biotech Hunter